Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens
Abhishek Maiti(The University of Texas MD Anderson Cancer Center), Caitlin R. Rausch(The University of Texas MD Anderson Cancer Center), Jörge E. Cortes(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Kiran Naqvi(The University of Texas MD Anderson Cancer Center), Maro Ohanian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Yesid Alvarado(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Nitin Jain(The University of Texas MD Anderson Cancer Center), Steven M. Kornblau(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Michael Andreeff(The University of Texas MD Anderson Cancer Center), Prithiviraj Bose(The University of Texas MD Anderson Cancer Center), Alessandra Ferrajoli(The University of Texas MD Anderson Cancer Center), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Lucia Masárová(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The University of Texas MD Anderson Cancer Center), Sa Wang(The University of Texas MD Anderson Cancer Center), Sergej Konoplev(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Jing Ning(The University of Texas MD Anderson Cancer Center), Wei Qiao(The University of Texas MD Anderson Cancer Center), John S. Welch(Washington University in St. Louis), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Marina Konopleva(The University of Texas MD Anderson Cancer Center)
Cited by 173Open Access
Abstract
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. ] However, little is known about outcomes of patients after failure of front-line venetoclax-based regimens. We found that patients failing front-line VEN+HMA have high-risk biology, dismal overall survival (OS) despite salvage therapy, and new putative mechanisms of resistance. This knowledge may help guide physicians' expectations, inform discussion with patients, and design clinical trials in patients after venetoclax failure.
Related Papers
No related papers found
Powered by citation graph analysis